Exploiting DNA repair defects for novel cancer therapies

Most human tumors accumulate a multitude of genetic changes due to defects in the DNA damage response. Recently, small-molecule inhibitors have been developed that target cells with specific DNA repair defects, providing hope for precision treatment of such tumors. Here we discuss the rationale behi...

Descripción completa

Detalles Bibliográficos
Autores principales: van Gent, Dik C., Kanaar, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Cell Biology 2016
Materias:
MBoC Perspectives on Cell Biology and Human Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945134/
https://www.ncbi.nlm.nih.gov/pubmed/27418635
http://dx.doi.org/10.1091/mbc.E15-10-0698
_version_ 1782442873314082816
author van Gent, Dik C.
Kanaar, Roland
author_facet van Gent, Dik C.
Kanaar, Roland
author_sort van Gent, Dik C.
collection PubMed
description Most human tumors accumulate a multitude of genetic changes due to defects in the DNA damage response. Recently, small-molecule inhibitors have been developed that target cells with specific DNA repair defects, providing hope for precision treatment of such tumors. Here we discuss the rationale behind these therapies and how an important bottleneck—patient selection—can be approached.
format Online
Article
Text
id pubmed-4945134
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The American Society for Cell Biology
record_format MEDLINE/PubMed
spelling pubmed-49451342016-09-30 Exploiting DNA repair defects for novel cancer therapies van Gent, Dik C. Kanaar, Roland Mol Biol Cell MBoC Perspectives on Cell Biology and Human Health Most human tumors accumulate a multitude of genetic changes due to defects in the DNA damage response. Recently, small-molecule inhibitors have been developed that target cells with specific DNA repair defects, providing hope for precision treatment of such tumors. Here we discuss the rationale behind these therapies and how an important bottleneck—patient selection—can be approached. The American Society for Cell Biology 2016-07-15 /pmc/articles/PMC4945134/ /pubmed/27418635 http://dx.doi.org/10.1091/mbc.E15-10-0698 Text en © 2016 van Gent and Kanaar. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0). “ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society for Cell Biology.
spellingShingle MBoC Perspectives on Cell Biology and Human Health
van Gent, Dik C.
Kanaar, Roland
Exploiting DNA repair defects for novel cancer therapies
title Exploiting DNA repair defects for novel cancer therapies
title_full Exploiting DNA repair defects for novel cancer therapies
title_fullStr Exploiting DNA repair defects for novel cancer therapies
title_full_unstemmed Exploiting DNA repair defects for novel cancer therapies
title_short Exploiting DNA repair defects for novel cancer therapies
title_sort exploiting dna repair defects for novel cancer therapies
topic MBoC Perspectives on Cell Biology and Human Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945134/
https://www.ncbi.nlm.nih.gov/pubmed/27418635
http://dx.doi.org/10.1091/mbc.E15-10-0698
work_keys_str_mv AT vangentdikc exploitingdnarepairdefectsfornovelcancertherapies
AT kanaarroland exploitingdnarepairdefectsfornovelcancertherapies

Ejemplares similares